Abstract

Despite significant improvement in survival, rheumatic diseases (RD) are associated with premature mortality rates comparable to cardiovascular and neoplastic disorders. The aim of our study was to assess mortality, causes of death, and life expectancy in an inflammatory RD retrospective cohort and compare those with the general population as well as with the results of previously published studies in a systematic literature review. Patients with the first-time diagnosis of inflammatory RD during 2012–2019 were identified and cross-checked for their vital status and the date of death. Sex- and age-standardized mortality ratios (SMR) as well as life expectancy for patients with inflammatory RDs were calculated. The results of a systematic literature review were included in meta-standardized mortality ratio calculations. 11,636 patients with newly diagnosed RD were identified. During a total of 43,064.34 person-years of follow-up, 950 death cases occurred. The prevailing causes of death for the total cohort were cardiovascular diseases and neoplasms. The age- and sex-adjusted SMR for the total cohort was calculated to be 1.32 (1.23; 1.40). Patients with rheumatoid arthritis if diagnosed at age 18–19 tend to live for 1.63 years less than the general population, patients with spondyloarthritis—for 2.7 years less, patients with connective tissue diseases—for almost nine years less than the general population. The findings of our study support the hypothesis that patients with RD have a higher risk of mortality and lower life expectancy than the general population.

Highlights

  • Rheumatic diseases (RD) are generally regarded as non-fatal diseases, some of them are associated with premature mortality rates comparable to cardiovascular and neoplastic disorders

  • During the period between 2013–2019 we have identified 11636 patients with rheumatic diseases (RD) (6008 patients with Rheumatoid arthritis (RA), 3289 with SpA, and 2339 with systemic connective tissue diseases (CTD) and vasculitis)

  • We have found a significant increase in the mortality rate in the total cohort of inflammatory

Read more

Summary

Introduction

Rheumatic diseases (RD) are generally regarded as non-fatal diseases, some of them are associated with premature mortality rates comparable to cardiovascular and neoplastic disorders. Significant improvement in survival has been noted since the introduction of modern cytotoxic therapies into the treatment of inflammatory RD, but it is still estimated, that mortality rates for patients with inflammatory RD are 59–425% higher than those of the age- and sex-matched general population. The mortality rate is the highest for systemic connective tissue diseases (CTD) (such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc)) and systemic vasculitis (SV) patients (standardized mortality ratio (SMR) up to 5.25), and the loss in life expectancy at the time of birth compared with the general population is the greatest for female patients with SSc (34 years). Rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients have a less elevated risk for premature death (SMR 1.3–3.0), the loss in life expectancy is 5 to 7 years [1–5].

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call